SeekingAlpha · Mar 4, 2026
RF
NASDAQ · RFL
Rafael Holdings, Inc.
Real Estate · Real Estate - Services
$2.29
Up+$0.07 (+3.06%)
Updated Sep 11, 2026, 12:44 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 52.46M
- P/E ratio
- -1.65
- Dividend yield
- 0.00%
- 52-week range
- $1.12 – $3.96
- Volume
- 129.79K
- Avg. volume
- 125.73K
Price performance
RFL price history
1M range · 19 trading sessions · Daily adjusted prices
RFL closed at $2.29 after 19 trading sessions, up 16.24% for the selected period.
- Last close
- $2.29
- Period change
- +16.24%
- Period low
- $1.81
- Period high
- $2.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $2.42 | $2.4899 | $2.28 | $2.29 | 129.79K |
| Sep 8, 2026 | $2.68 | $2.7632 | $2.43 | $2.43 | 254.57K |
| Sep 4, 2026 | $2.49 | $2.74 | $2.49 | $2.56 | 138.59K |
| Sep 3, 2026 | $2.51 | $2.6397 | $2.391 | $2.47 | 77.26K |
| Sep 2, 2026 | $2.43 | $2.65 | $2.43 | $2.51 | 85.93K |
| Sep 1, 2026 | $2.55 | $2.55 | $2.34 | $2.44 | 90.5K |
| Aug 31, 2026 | $2.56 | $2.6499 | $2.37 | $2.57 | 98.29K |
| Aug 28, 2026 | $2.39 | $2.8189 | $2.39 | $2.56 | 304.68K |
| Aug 27, 2026 | $2.31 | $2.52 | $2.30 | $2.37 | 128.54K |
| Aug 26, 2026 | $2.27 | $2.35 | $2.20 | $2.29 | 90.75K |
| Aug 25, 2026 | $2.22 | $2.3194 | $2.18 | $2.24 | 83.11K |
| Aug 24, 2026 | $2.16 | $2.20 | $2.03 | $2.19 | 116.64K |
| Aug 21, 2026 | $1.85 | $2.20 | $1.85 | $2.16 | 142.25K |
| Aug 20, 2026 | $1.82 | $1.94 | $1.77 | $1.85 | 79.27K |
| Aug 19, 2026 | $1.973 | $1.973 | $1.77 | $1.81 | 149.83K |
| Aug 18, 2026 | $1.86 | $1.90 | $1.82 | $1.86 | 65.99K |
| Aug 17, 2026 | $1.99 | $2.075 | $1.87 | $1.87 | 109.47K |
| Aug 14, 2026 | $2.00 | $2.11 | $1.90 | $1.99 | 177.68K |
| Aug 13, 2026 | $2.04 | $2.16 | $1.97 | $1.97 | 57.35K |
Latest RFL news
The latest Smart Investors Daily articles mentioning RFL.
Stock researchCompany · Overview
RFL research
Overview
Company profile and research snapshot.
Company profile
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
globenewswire.com · Dec 11, 2025
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
